All In MedTech

Device Trial Radar · NCT06590467

Abbott Structural Heart Device Registry

Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

2,500

Planned (sponsor's estimate)

Start

Aug 21, 2024

Primary completion

Dec 2029

Study completion Nov 2039

Sponsor

Lead sponsor
Abbott Medical DevicesPublic (ABT)
Sponsor type
Industry
First posted
Sep 19, 2024

More device trials from this sponsor

Design

Study type
Observational
FDA-regulated device
Yes
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The Abbott Structural Heart (SH) Registry is being conducted to confirm the safety and performance of Abbott's SH devices in a post-market, real-world setting. The Registry primarily involves gathering data from routine hospital practices and standard-of-care (SOC) procedures administered to patients. All devices used in these procedures must be commercially available to the participating site. A list of specific devices covered by the Registry are available upon request from the Sponsor. Data generated by the Registry will be used to meet regulatory requirements, such as the European Union Medical Device Regulations 2017/745, that require active post-market clinical follow-up (PMCF) for all commercially available devices.

Conditions

  • Heart Diseases
  • ASD - Atrial Septal Defect
  • VSD - Muscular Ventricular Septal Defect
  • PFO - Patent Foramen Ovale
  • PIVSD - Post Infarct Muscular Ventricular Septal Defect
  • Valvular Heart Disease

Interventions

  • Amplatzer™ Occlusion DevicesDevice

    The Amplatzer™ Occluders are devices intended for the occlusion of multiple septal heart defects.

  • Epic™ Surgical Tissue Heart Valve devicesDevice

    The Epic™ valves are indicated for patients requiring replacement of a diseased, damaged, or malfunctioning native aortic/mitral heart valve. It may also be used as a replacement for a previously implanted aortic/mitral prosthetic heart valve.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Primary Safety EndpointTime frame: 7 days
  2. Primary Effectiveness EndpointTime frame: Baseline

Locations

36 sites in 10 countries. Site status is shown where the registry gives one.

  • USC University Hospital

    Los Angeles, California · Not yet recruiting

  • MedStar Washington Hospital Center

    Washington D.C., District of Columbia · Not yet recruiting

  • Baptist Hospital of Miami

    Miami, Florida · Not yet recruiting

33 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.